MedTrace Logo

TURBt With Adjuvant Cryoablation to Treat Bladder Cancer

NCT02760953 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2017-10-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of applying cryoablation as an adjuvant therapy with TUR to treat bladder tumor.

Conditions

  • Urinary Bladder Neoplasms

Interventions

PROCEDURE

Cryoablation

Using a novel cryoablation unit to perform transurethral cryoablation on the tumor base after transurethral resection

DRUG

Epirubicin

Epirubicin instillation should be give within 24 hours after initial TUR, this is accord with current guideline.

Sponsors & Collaborators

  • Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

    collaborator OTHER

  • Shanghai Zhongshan Hospital

    collaborator OTHER

  • Shanghai 5th People's Hospital

    collaborator OTHER

  • Zhejiang Provincial People's Hospital

    collaborator OTHER

  • Huashan Hospital

    lead OTHER

Principal Investigators

  • Haowen Jiang, Doctor · Huashan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-19
Primary Completion
2018-10-30
Completion
2018-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02760953 on ClinicalTrials.gov